[HTML][HTML] Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
A D'Urzo, GT Ferguson, JA van Noord, K Hirata… - Respiratory …, 2011 - Springer
Background NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic
antagonist glycopyrronium bromide in development for the treatment of chronic obstructive …
antagonist glycopyrronium bromide in development for the treatment of chronic obstructive …
[HTML][HTML] The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease
…, DH Dockrell, S Doe, J Duckers, A d'Urzo… - The Lancet …, 2021 - thelancet.com
Persistent ill health after acute COVID-19—referred to as long COVID, the post-acute COVID-19
syndrome, or the post-COVID-19 condition—has emerged as a major concern. We …
syndrome, or the post-COVID-19 condition—has emerged as a major concern. We …
[HTML][HTML] Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD …
AD D'Urzo, SI Rennard, EM Kerwin, V Mergel… - Respiratory …, 2014 - Springer
Background Combining two long-acting bronchodilators with complementary mechanisms
of action may provide treatment benefits to patients with chronic obstructive pulmonary …
of action may provide treatment benefits to patients with chronic obstructive pulmonary …
Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)
EM Kerwin, AD D'Urzo, AF Gelb, H Lakkis… - COPD: Journal of …, 2012 - Taylor & Francis
Background: This Phase III study evaluated the efficacy and safety of twice-daily aclidinium
200 μg and 400 μg versus placebo in the treatment of moderate-to-severe COPD. Methods: …
200 μg and 400 μg versus placebo in the treatment of moderate-to-severe COPD. Methods: …
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study
DA Mahler, M Decramer, A D'Urzo… - European …, 2014 - Eur Respiratory Soc
We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and
glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic …
glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic …
Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind …
DA Mahler, A D'Urzo, ED Bateman, SA Özkan, T White… - Thorax, 2012 - thorax.bmj.com
Background Current guidelines recommend treatment with one or more long-acting
bronchodilators for patients with moderate or more severe chronic obstructive pulmonary disease (…
bronchodilators for patients with moderate or more severe chronic obstructive pulmonary disease (…
[HTML][HTML] Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month …
ED Bateman, KR Chapman, D Singh, AD D'Urzo… - Respiratory …, 2015 - Springer
Background The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol
fumarate, a long-acting beta 2 -agonist (400/12 μg twice daily) achieves improvements …
fumarate, a long-acting beta 2 -agonist (400/12 μg twice daily) achieves improvements …
Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD–2019 update of evidence
…, SD Aaron, M Balter, MF Beauchesne, A D'Urzo… - 2019 - Taylor & Francis
In this guideline update, we highlight important and new findings related to pharmacological
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …
[HTML][HTML] Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review
M Miravitlles, A D'Urzo, D Singh, V Koblizek - Respiratory Research, 2016 - Springer
Identifying patients at risk of exacerbations and managing them appropriately to reduce this
risk represents an important clinical challenge. Numerous treatments have been assessed …
risk represents an important clinical challenge. Numerous treatments have been assessed …
[HTML][HTML] A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the …
…, KM Beeh, J Beier, ED Bateman, A D'Urzo… - BMC pulmonary …, 2014 - Springer
Background Two once-daily long-acting muscarinic antagonists (LAMAs) are currently
available for the treatment of chronic obstructive pulmonary disease (COPD) – tiotropium and …
available for the treatment of chronic obstructive pulmonary disease (COPD) – tiotropium and …